FDA Pushes Forward on Transparency

February 2010
Pharmaceutical Representative;Feb2010, Vol. 40 Issue 2, p11
The article offers updates concerning the U.S. Food & Drug Administration (FDA). The FDA released the first part of its transparency plan which aims to make government action more open to people and to make drug manufacturers more aware of the approval process. Meanwhile, the drugs actemra of Genentech Inc. and qutenza of NeurogesX Inc. have been approved by the FDA. Shire Ltd. has released the drug Intuniv, a treatment for attention-deficit hyperactivity disorder in children.


Related Articles

  • FDA actions.  // OB/GYN Clinical Alert;Apr2010 Pharmacology, p2 

    The article offers news briefs in the pharmaceutical industry in the U.S. The Food and Drug Administration (FDA) warned that long-acting beta agonists (LABA) like salmeterol and formoterol should not be used alone in treating asthma in children and adults. FDA approved Wyeth Pharmaceuticals...

  • Applications Update.  // PharmaWatch: Biotechnology;Jun2010, Vol. 9 Issue 6, p9 

    The article offers updates on issues related biotechnology industry. Avanir Pharmaceuticals submits complete response to the U.S. Food and Drug Administration (FDA) for pseudobulbar affect (PBA) drug. Shire PLC receives notice letter from Anchen Pharmaceutical for attention deficit hyperactivity...

  • CHAIN PHARMACY: REPORTERS Notebook.  // Drug Store News;11/16/2009, Vol. 31 Issue 14, p20 

    The article offers news briefs related to the pharmaceutical industry in the U.S. British drug maker Shire PLC announces that its attention deficit hyperactivity disorder drug Vyvanse (lisdexamfetamine dimesylate) received five-year market exclusivity from the Food and Drug Administration (FDA)....

  • Shire's Vpriv Gets Official FDA Nod.  // Bioworld Week;3/8/2010, Vol. 18 Issue 10, p2 

    The article reports on the U.S. Food and Drug Administration (FDA) approval of the Vpriv (velaglucerase) drug for Gasucher's disease by Basingtoke, Great Britain-based Shire PLC.

  • Regulatory Regime.  // U.S. Pharma & Healthcare Report;Q2 2010, p13 

    This article discusses the regulatory regime surrounding the U.S. pharmaceutical market. The Food and Drug Administration (FDA) is responsible for the regulation of pharmaceuticals in the country. Particular focus is given to the prime tasks of the FDA, which will receive a 23% increase in its...

  • FDA Approves MAb for Rheumatoid Arthritis.  // BioPharm International;Feb2010, Vol. 23 Issue 2, p12 

    The article reports on the approval of Genentech Inc.'s drug, Actemra as treatment for moderate to severe rheumatoid arthritis by the U.S. Food and Drug Administration.

  • Genentech hedged early on Avastin. Iskowitz, Marc // Medical Marketing & Media;Jan2012, Vol. 47 Issue 1, p18 

    The article reports on the move of Genentech Inc. to cancel all its promotional campaigns for Avastin, a drug indicated for metastatic breast cancer, following the decision of the U.S. Food and Administration (FDA) commissioner Margaret Hamburg to revoke drug's approval.

  • Ranibizumab approved for ME after RVO. Krader, Cheryl Guttman // Ophthalmology Times;7/15/2010, Vol. 35 Issue 14, p1 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to Genentech Inc. to market ranibizumab injection (Lucentis) for treating macular edema (ME) following retinal vein occlusion (RVO).

  • Launch of Genentech's Raptiva Moves Toward Final FDA Approval. Mirasol, Feliza // Chemical Market Reporter;9/15/2003, Vol. 264 Issue 8, p10 

    Reports on the recommendation of the U.S. Food and Drug Administration (FDA) advisory committee to consider the approval of Genentech Inc.'s psoriasis drug Raptiva. Consideration of FDA's safety concerns over manufacturing consistency; Addition of Phase III clinical data; Assessment of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics